The neuroradiologist of MTB took into account the following: the patient clinical status (asymptomatic), the MGMT promoter methylation of glioma, the time elapsed after the end of radiotherapy, the contrast enhancement pattern of the lesion (“swiss cheese”), and the ADC values (absolute value at MRI follow-up and compared to the pre-treatment MRI value, both recalculated by the MTB neuroradiologist), and proposed pseudo-progression as the diagnostic hypothesis. This evidence concerns the gene MGMT and central nervous system cancer.